U.S. markets open in 5 hours 50 minutes
  • S&P Futures

    3,853.25
    +44.00 (+1.16%)
     
  • Dow Futures

    31,240.00
    +328.00 (+1.06%)
     
  • Nasdaq Futures

    13,118.00
    +207.00 (+1.60%)
     
  • Russell 2000 Futures

    2,249.10
    +49.90 (+2.27%)
     
  • Crude Oil

    62.58
    +1.08 (+1.76%)
     
  • Gold

    1,749.60
    +20.80 (+1.20%)
     
  • Silver

    27.00
    +0.56 (+2.10%)
     
  • EUR/USD

    1.2057
    -0.0031 (-0.25%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    25.06
    -3.83 (-13.26%)
     
  • GBP/USD

    1.3934
    +0.0012 (+0.08%)
     
  • USD/JPY

    106.6100
    +0.1080 (+0.10%)
     
  • BTC-USD

    47,060.39
    +2,557.55 (+5.75%)
     
  • CMC Crypto 200

    941.69
    +8.56 (+0.92%)
     
  • FTSE 100

    6,592.97
    +109.54 (+1.69%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

BioNTech to offer vaccine to its own workers

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BERLIN, Jan 11 (Reuters) - BioNTech will offer its coronavirus vaccine to all its employees, it said on Monday, sidestepping Germany's official inoculation programme in what it said was a bid to protect its supply chain from COVID-19 outbreaks.

The German company, which developed the vaccine with U.S. drugmaker Pfizer, said in a statement it would also offer the shot to its suppliers and distributors in Austria.

"To maintain the integrity of our supply chain, including the development, production, approval, supply and distribution of the vaccine, BioNTech has decided to offer a voluntary COVID-19 vaccination to its employees in Germany," it said.

The company is under pressure to ramp up production of the shot that many hope will help the world defeat the pandemic.

"The additional small quantities of vaccine used for this purpose are separate and distinct from those committed under the supply agreements entered into with the European Commission and other governments, and will not impact BioNTech's ability to meet its commitments under these supply agreements," it added. (Reporting by Joseph Nasr Editing by Peter Graff)